Literature DB >> 12843172

Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis.

Ele Ferrannini1, Amalia Gastaldelli, Masafumi Matsuda, Yoshinori Miyazaki, Maura Pettiti, Leonard Glass, Ralph A DeFronzo.   

Abstract

Both ethnicity and familial diabetes (FHD) confer risk for type 2 diabetes [diabetes mellitus (DM)], but their relative influence has not been established. To analyze the separate impact of ethnicity, Mexican-American vs. Caucasian, and FHD on the physiological determinants of glucose tolerance, we measured insulin sensitivity of glucose uptake (IS(GU)) (by the clamp technique), endogenous glucose production (by 3-[(3)H]glucose infusion), and insulin secretory response (to oral glucose) in 172 Mexican-Americans and 60 Caucasians with normal glucose tolerance (NGT) or DM. IS(GU) was markedly reduced in diabetics vs. NGT (3.9 +/- 0.2 vs. 8.4 +/- 0.5 ml.min(-1).kg(ffm)(-1), P < 0.0001), and lower in Mexican-Americans than in Caucasians (5.3 +/- 0.3 vs. 7.3 +/- 0.7 ml.min(-1).kg(ffm)(-1), P < 0.003; ffm, fat-free mass). In a multivariate analysis including both ethnicity and FHD (and adjusting for body mass index, age, and diabetes), ethnicity was still a significant (P = 0.02) independent correlate of IS(GU). Insulin resistance of glucose production was increased in diabetics (14 +/- 1 mmol.min(-1).[ micro U/ml], P < 0.0001 vs. 9 +/- 1 of NGT), whereas the 30' insulin/glucose ratio was decreased (16 +/- 1 micro U/mg, P < 0.0001 vs. 60 +/- 5). In multivariate models, neither ethnicity nor FHD were significant independent correlates of glucose production and early insulin response. We conclude that the primary physiological target of the propensity to diabetes of Mexican-Americans is insulin resistance of glucose uptake.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843172     DOI: 10.1210/jc.2002-021864

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.

Authors:  Jaime A Davidson; Richard Aguilar; Fernando J Lavalle González; Angelina Trujillo; Maria Alba; Ujjwala Vijapurkar; Gary Meininger
Journal:  Ethn Dis       Date:  2016-04-21       Impact factor: 1.847

2.  Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement.

Authors:  Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton
Journal:  J Clin Endocrinol Metab       Date:  2012-06-22       Impact factor: 5.958

Review 3.  Understanding the growing epidemic of type 2 diabetes in the Hispanic population living in the United States.

Authors:  Cristina Aguayo-Mazzucato; Paula Diaque; Sonia Hernandez; Silvia Rosas; Aleksandar Kostic; Augusto Enrique Caballero
Journal:  Diabetes Metab Res Rev       Date:  2018-12-04       Impact factor: 4.876

4.  Ethnicity, obesity and the metabolic syndrome: implications on assessing risk and targeting intervention.

Authors:  Mark D Deboer
Journal:  Expert Rev Endocrinol Metab       Date:  2011-03

Review 5.  Diabetes in the Hispanic or Latino population: genes, environment, culture, and more.

Authors:  A Enrique Caballero
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

Review 6.  The aetiology and molecular landscape of insulin resistance.

Authors:  David E James; Jacqueline Stöckli; Morris J Birnbaum
Journal:  Nat Rev Mol Cell Biol       Date:  2021-07-20       Impact factor: 94.444

7.  Race/ethnic difference in diabetes and diabetic complications.

Authors:  Elias K Spanakis; Sherita Hill Golden
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

8.  Resistance Training in Type II Diabetes Mellitus: Impact on Areas of Metabolic Dysfunction in Skeletal Muscle and Potential Impact on Bone.

Authors:  Richard J Wood; Elizabeth C O'Neill
Journal:  J Nutr Metab       Date:  2012-02-06

9.  Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.

Authors:  Jaime A Davidson; Rosemarie Lajara; Richard B Aguilar; Michaela Mattheus; Hans-Juergen Woerle; Maximilian von Eynatten
Journal:  BMJ Open Diabetes Res Care       Date:  2014-04-16

Review 10.  Skeletal muscle insulin resistance is the primary defect in type 2 diabetes.

Authors:  Ralph A DeFronzo; Devjit Tripathy
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.